Jiangsu Aidea Pharmaceutical Co Ltd (688488) - Net Assets
Based on the latest financial reports, Jiangsu Aidea Pharmaceutical Co Ltd (688488) has net assets worth CN¥974.37 Million CNY (≈ $142.58 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.98 Billion ≈ $289.01 Million USD) and total liabilities (CN¥1.00 Billion ≈ $146.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Jiangsu Aidea Pharmaceutical Co Ltd (688488) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥974.37 Million |
| % of Total Assets | 49.33% |
| Annual Growth Rate | 15.2% |
| 5-Year Change | -18.06% |
| 10-Year Change | N/A |
| Growth Volatility | 49.04 |
Jiangsu Aidea Pharmaceutical Co Ltd - Net Assets Trend (2016–2025)
This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 688488 market cap overview.
Annual Net Assets for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2025)
The table below shows the annual net assets of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025. Also explore 688488 shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.07 Billion ≈ $157.05 Million |
+0.58% |
| 2024-12-31 | CN¥1.07 Billion ≈ $156.15 Million |
-5.19% |
| 2023-12-31 | CN¥1.13 Billion ≈ $164.70 Million |
-6.12% |
| 2022-12-31 | CN¥1.20 Billion ≈ $175.45 Million |
-8.46% |
| 2021-12-31 | CN¥1.31 Billion ≈ $191.66 Million |
-3.68% |
| 2020-12-31 | CN¥1.36 Billion ≈ $198.99 Million |
+144.47% |
| 2019-12-31 | CN¥556.24 Million ≈ $81.39 Million |
+6.41% |
| 2018-12-31 | CN¥522.71 Million ≈ $76.49 Million |
+1.68% |
| 2017-12-31 | CN¥514.09 Million ≈ $75.23 Million |
+71.14% |
| 2016-12-31 | CN¥300.40 Million ≈ $43.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Aidea Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1277.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.32 Billion | 136.72% |
| Total Equity | CN¥964.68 Million | 100.00% |
Jiangsu Aidea Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangsu Aidea Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Econergy Renewable Energy Ltd
TA:ECNR
|
$944.63 Million |
|
Piraeus Port Authority S.A
AT:PPA
|
$945.00 Million |
|
WAM Capital Ltd
AU:WAM
|
$945.12 Million |
|
Hyosung TNC Corp
KO:298020
|
$945.27 Million |
|
Critical Metals Corp. Ordinary Shares
NASDAQ:CRML
|
$944.49 Million |
|
Shandong Intco Recycling Resources Co Ltd
SHG:688087
|
$944.46 Million |
|
Shanghai AJ Group Co Ltd
SHG:600643
|
$944.18 Million |
|
Aksa Akrilik Kimya Sanayi AS
IS:AKSA
|
$944.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Aidea Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 980,894,898 to 964,679,379, a change of -16,215,519 (-1.7%).
- Net loss of 19,733,700 reduced equity.
- Dividend payments of 20,871,235 reduced retained earnings.
- Other comprehensive income decreased equity by 16,290,707.
- Other factors increased equity by 40,680,122.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-19.73 Million | -2.05% |
| Dividends Paid | CN¥20.87 Million | -2.16% |
| Other Comprehensive Income | CN¥-16.29 Million | -1.69% |
| Other Changes | CN¥40.68 Million | +4.22% |
| Total Change | CN¥- | -1.65% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Aidea Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.09x to 6.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥0.80 | CN¥15.34 | x |
| 2017-12-31 | CN¥1.38 | CN¥15.34 | x |
| 2018-12-31 | CN¥1.40 | CN¥15.34 | x |
| 2019-12-31 | CN¥1.49 | CN¥15.34 | x |
| 2020-12-31 | CN¥3.42 | CN¥15.34 | x |
| 2021-12-31 | CN¥3.06 | CN¥15.34 | x |
| 2022-12-31 | CN¥2.90 | CN¥15.34 | x |
| 2023-12-31 | CN¥2.66 | CN¥15.34 | x |
| 2024-12-31 | CN¥2.33 | CN¥15.34 | x |
| 2025-12-31 | CN¥2.44 | CN¥15.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Aidea Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.74%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.98x
- Recent ROE (-2.05%) is above the historical average (-2.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 4.74% | 5.52% | 0.58x | 1.48x | CN¥-15.80 Million |
| 2017 | -7.39% | -27.88% | 0.21x | 1.28x | CN¥-89.40 Million |
| 2018 | 1.65% | 3.11% | 0.39x | 1.36x | CN¥-43.65 Million |
| 2019 | 6.05% | 9.75% | 0.44x | 1.40x | CN¥-21.97 Million |
| 2020 | 2.92% | 13.76% | 0.20x | 1.06x | CN¥-96.21 Million |
| 2021 | -2.29% | -11.73% | 0.18x | 1.10x | CN¥-160.97 Million |
| 2022 | -10.35% | -50.81% | 0.15x | 1.38x | CN¥-243.99 Million |
| 2023 | -6.76% | -18.49% | 0.24x | 1.55x | CN¥-188.62 Million |
| 2024 | -14.40% | -33.80% | 0.22x | 1.91x | CN¥-239.29 Million |
| 2025 | -2.05% | -2.74% | 0.38x | 1.98x | CN¥-116.20 Million |
Industry Comparison
This section compares Jiangsu Aidea Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $923,055,083
- Average return on equity (ROE) among peers: 12.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Aidea Pharmaceutical Co Ltd (688488) | CN¥974.37 Million | 4.74% | 1.03x | $944.54 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.02 Million | 9.34% | 2.79x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.37 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $-14.51 Million | 0.00% | 0.00x | $483.41 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $915.76 Million | -0.65% | 0.06x | $575.51 Million |
| Chengzhi Shareholding Co Ltd (000990) | $160.52 Million | 17.55% | 0.67x | $1.61 Billion |
| Hualan Biological EngineeringInc (002007) | $5.77 Billion | 19.74% | 0.12x | $3.46 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.10 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $4.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $817.45 Million | 8.40% | 0.36x | $428.14 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $396.33 Million | 29.23% | 0.30x | $1.62 Billion |
About Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules… Read more